Press Releases

22 Jul 2022

Xbrane Biopharma releases interim report for January – June 2022

20 Jul 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2022 on July 22, 2022

04 Jul 2022

Xbrane provides update on ranibizumab biosimilar candidate FDA filing

30 Jun 2022

Xbrane Biopharma AB (“Xbrane” or the “Company”) announces changes to the number of shares and votes in the Company.

17 Jun 2022

Members of Xbrane’s management team sell shares to pay taxes but remain dedicated and long-term employees and shareholders

30 May 2022

Xbrane provides update on ranibizumab biosimilar candidate FDA filing

05 May 2022

Announcement from Xbrane Biopharma’s annual general meeting

05 May 2022

Xbrane Biopharma releases interim report for January – March 2022

02 May 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2022 on May 5, 2022.

05 Apr 2022

Correction regarding notice of annual general meeting in Xbrane Biopharma

04 Apr 2022

Notice of annual general meeting in Xbrane Biopharma AB

31 Mar 2022

Xbrane Biopharma releases annual report 2021

24 Feb 2022

Xbrane Biopharma releases Year-end report 2021

22 Feb 2022

Invitation to presentation of Xbrane Biopharma’s Year-end report 2021 on February 24, 2022.

17 Feb 2022

Xbrane provides an update on its subsidiary Primm Pharma

Subscribe to updates regarding Xbrane